Hospital Acquired Infections: Testing Markets


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Hospital Acquired Infections: Testing Markets

  1. 1. Hospital Acquired Infections: Testing MarketsReport Details:Published:August 2012No. of Pages: 117Price: Single User License – US$3995A nosocomial, or hospital-acquired, infection is a new infection that develops in a patient duringhospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admissionare excluded. This type of infection is also known as a hospital-acquired infection (or moregenerically healthcare-associated infections). The following are among the hospital infectionsconsidered in this report:•Acinetobacter Baumannii•Clostridium Difficile•Hospital-Acquired Pneumonia•Pseudomonas Aeruginosa•Staphylococcus Aureus•Tuberculosis•Urinary Tract Infections•Vancomycin-resistant Enterococcus•Ventilator-Associated PneumoniaThis report focuses on testing for nosocomial infections. The major consideration is given tobacterial nosocomial infections because a) they are the most frequent type of infections spread inthe hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningfulbased both on medial considerations and on market considerations. This report Hospital AcquiredInfection Testing Markets looks at the market for diagnostics that address the growing nosocomialinfection threat. As part of its coverage, the report includes the following information:•Market Size Estimate and Growth Forecast for the HAI Diagnostics Market•Issues and Trends Affecting Market•Common Hospital (nosocomial) Infections•Nosocomial Infection Statistics•International Hospital Length of Stay Statistics•The Role of Molecular Tests vs. Traditional•Corporate Profiles of Key SuppliersMarket analysis in this report considers primarily the epidemiological considerations and the sizespatient groups both in the United States and globally, where available. We have accumulated themost recent data available, understanding that virtually no organization does extensive studies on
  2. 2. these applications on a regular basis. Many studies are highly localized and may only apply to acommunity, state or country (more often countries that are not a part of the major markets fornosocomial diagnostic and therapeutic products). In many instances, we have had to draw frombroader epidemiologic data, that is, on data that reach outside of the hospital environment in orderto try and construct a picture of the nosocomial testing and treatment needs.The primary focus of this report is on the bacterial form of nosocomial infections, and those withsignificant impact on the hospital setting and markets. In looking at these infections, we considerthe diagnostic and therapeutic technologies that are currently available and attempt to projecttrends for diagnosing these infections. To some extent, we are limited by the activity of theindustries associated with the diagnosis and treatment of these infections. For the most part, theseactivities are limited and the advanced technologies seen in other areas of medical application arenot necessarily present in terms of microbiology.Companies Profiled in the report include the following:•Abbott Laboratories•Alere•Becton, Dickinson•bioMerieux•Cephei•Gen-Probe•Meridian Bioscience, Inc.•Qiagen GmbH•Roche•Siemens AGThe analysis presented in this report is based on data from a combination of company,government, industry, institutional and private sources. It includes information from extensiveliterature reviews and discussions with experts in the field, including microbiologists, pathologists,hospital authorities, research scientists, business development managers and marketingmanagers.Get your copy of this report @ points covered in Table of Contents of this report includeTable of ContentsCHAPTER ONE: EXECUTIVE SUMMARYOverviewInfection Control SummaryScope and MethodologyTotal Size and Growth of the MarketIssues and Trends Affecting Market
  3. 3. Molecular Testing vs. Conventional TestingLeading CompetitorsCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDSOverviewIntroduction to PathogensClassification of Antibacterial OrganismsCommon Hospital (nosocomial) InfectionsDescription of InfectionsAcinetobacter BaumanniiClostridium DifficileGastroenteritisHospital-Acquired Pneumonia (HAP)Pseudomonas AeruginosaStaphylococcus Aureus/Methicillin-Resistant Staphylococcus AureusStenotrophomonas MaltophiliaTuberculosisUrinary Tract InfectionsVancomycin-Resistant EnterococcusHospital Units and Infection RisksBurn UnitsIntensive Care UnitsEmergency DepartmentsPrinciples of Anti-bacterial TherapyInfecting OrganismAntibiotic Sensitivity TestingSite of InfectionHost Defenses and Organ FunctionAntibiotic PharmacokineticsMonitoring TherapyGeneral Infection StatisticsNosocomial Infection StatisticsPopulations at Risk for InfectionDemographics of the WorldInfections and Drug ResistanceCauses of Drug ResistanceAntibiotic AbuseAntibiotic Use in AgricultureDrug Resistance in Select PopulationsChildrenThe Elderly
  4. 4. Compromised IndividualsMeasures for Reducing ResistanceAntibiotic CyclingAntibiotic EducationScreening Hospitalized patientsThe American Recovery and Reinvestment Act of 2009Financial Impact of Hospital InfectionsState Level Case Study of HAI Admissions and ReadmissionsManufacturer and Marketer TrendsTrends in Partnerships and AlliancesDevelopers TrendsCHAPTER THREE: HOSPITAL INFECTION DIAGNOSTICSOverviewMethods of TransmissionAirborneContactDirect-Contact TransmissionIndirect-Contact TransmissionDropletVehiclePrevention MeasuresTestingDrug-Resistance/Susceptibility TestingGenotypic MethodsDNA SequencingSolid-phase Hybridization TechniquesMicroarraysReal-time Polymerase Chain Reaction TechniquesPhenotypic MethodsPhage-based AssaysColorimetric MethodsThe Nitrate Reductase AssayNosocomial Disease TestingAcinetobacter BaumanniiClostridium DifficileHospital-Acquired PneumoniaVentilator-Associated PneumoniaPseudomonas AeruginosaStaphylococcus Aureus
  5. 5. TuberculosisUrinary Tract InfectionsNew DevelopmentsMarket OverviewTotal Market Size and ForecastHAI Testing by Infection TypeHospital Infection Testing Market by Geographical RegionMolecular Testing vs. Conventional Testing.Market and Forecast for Molecular HAICompetitors in HAI TestingCHAPTER FOUR: TREATING HOSPITAL INFECTIONSOverviewTreatment GuidelinesClostridium DifficileGastroenteritisHospital-Acquired PneumoniaVentilator-associated PneumoniaPseudomonas AeruginosaStaphylococcus AureusStenotrophomonas maltophiliaTuberculosisUrinary Tract InfectionsRecent Drug ApprovalsMarket OverviewCHAPTER FIVE: MARKET SUMMARYMarket ConsiderationsMarket OverviewRegional Breakdown of MarketCompetitive SummaryCHAPTER SIX: COMPANY PROFILESIntroductionAbbott LaboratoriesAdvanDx, Inc.AlereAstraZenecaBayer Healthcare Pharmaceuticals (Bayer Schering Pharma) v Becton, Dickinson
  6. 6. CepheidCubist PharmaceuticalsDaiichi SankyoDiatherix Laboratories Inc.Gen-Probe Inc.GlaxoSmithKlineJohnson & JohnsonMerck & Co.Meridian Bioscience, Inc.PfizerRocheSeegene, Inc.APPENDIX: LIST OF MAJOR PROVIDERSList Of ExhibitsCHAPTER ONE: EXECUTIVE SUMMARYTable 1-2: The Global Market for Hospital Infections by Product Segment (Diagnostics,Treatment), 2005-2015Figure 1-1: The Global Market for Hospital Infections 2005-2015Figure 1-2: Growth Rate - HAI Diagnostic Market vs. HAI Treatment MarketTable 1-3: MRSA Risk and Testing PriorityCHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDSTable 2-1: Antibiotics with Difficult PenetrationTable 2-2: Common Nosocomial InfectionsTable 2-3: Risk Factors for M. tuberculosisTable 2-4: Common ICU InfectionsTable 2-5: Estimated World and U.S. Incidence of Bacterial InfectionsFigure 2-1: Estimated World and U.S. Incidence of Bacterial InfectionsFigure 2-2: U.S. Hospital Admissions, Percent Acquiring HAIsTable 2-6: World Population at Risk for Serious Bacterial Infections, Secondary to ChronicDiseases by Selected Geographical Region (World, U.S., Europe), 2010Figure 2-3: World Population at Risk for Serious Bacterial Infections, Secondary to ChronicDiseases by Selected Geographical Region, 2010Table 2-4: Estimated World Population by Age and Geographical Region, 2010Figure 2-4: Estimated World Population by Age and Geographical Region, 2010Table 2-5: Pennsylvania State Analysis of HAI Readmissions and Related Costs, 2009Table 2-6: Pennsylvania State Analysis of HAIs, 2009CHAPTER THREE: HOSPITAL INFECTION DIAGNOSTICSTable 3-1: CDC Healthcare Setting GuidelinesTable 3-2: MRSA Risk and Testing Priority
  7. 7. Table 3-3: Recent Approvals for Hospital Infection Testing (Product, Company, Description ofTest, Approved Regions)Table 3-4: New Developments, Hospital Infection Testing (Developer, Description, Status,Indication)Table 3-5: The World Market for Hospital Infection Testing/Diagnostics 2005-2015 (Revenues,Percent Change)Figure 3-1: The World Market for Hospital Infection Testing/Diagnostics 2005-2015Figure 3-2: Distribution of Revenues for HAI Testing by Infection Type, 2010 Estimates (MRSA,Cdiff, Other HAIs)Table 3-6: The World Market for Hospital Infection Testing/Diagnostics Estimated Products Salesby Geographic Region (US, Europe, ROW) 2005-2015Figure 3-3: The World Market for Hospital Infection Testing/Diagnostics Estimated Product Salesby Geographic Region (US, Europe, ROW) 2005-2015Table 3-7: Detection Time for MRSA by Screening Method (Test Type, Turnaround Time, AverageCost)Figure 3-4: Molecular vs. Conventional Diagnostic Market for HAIs in 2010 and Projected to 2015Table 3-8: The World Market for Hospital Infection Diagnostics (Top 9 Leading Suppliers vs.Others) 2010CHAPTER FOUR: TREATING HOSPITAL INFECTIONSTable 4-1: Treatment Options for Bacterial Infections (Type, Brand, and Manufacturer)Table 4-3: Recent Approvals for Hospital Infection TreatmentsTable 4-5: The World Market for Hospital Infection Treatment 2005-2015Figure 4-3: The World Market for Hospital Infection Treatment Estimated Market Share by Region,2010CHAPTER FIVE: MARKET SUMMARYTable 5-1: The Global Market for Hospital Infections by Product Segment, 2005-2015Figure 5-1: The Global Market for Hospital Infection Products 2005-2015Figure 5-2: The Global Market for Hospital Infection Products by Product Segment, 2010(Diagnostics, Treatment)Contact: for more information.